The effect of OA on proliferation and polyamine metabolism of K 562 leukemic cells and their responsiveness to natural killer cell activity. 1995

K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
Department of Animal Physiology, Veterinary Faculty, Warsaw Agricultural University, Poland.

Orotic acid (OA), a known promoter of carcinogenesis, significantly stimulated proliferation of K 562 leukemic cells even at as high a concentration as 0.1 mM. This effect was accompanied by a significant increase of the activity of two key enzymes of the polyamine pathway, i.e. ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC). The induction of ODC activity was associated with increased expression of the ODC gene. The participation of ODC in early events evoked by OA in leukemic cells was confirmed by the decrease of the stimulatory effect of OA on cell proliferation in the presence of alpha-difluoromethylornithine (DFMO)--an irreversible inhibitor of ODC. The involvement of protein kinase C (PK-C) and cyclic nucleotide-dependent kinases in OA action on K 562 leukemic cells was demonstrated by a significant reduction of cell proliferation by addition of H-7 (1-(5-isoquinolinesulphonyl)-2-methylpiperazine). Since PK-C is involved both in induction of ODC activity and in membrane transport of polyamines, H-7 significantly inhibited the proliferation of K 562 leukemic cells even in the presence of OA and exogenous putrescine. The importance of extracellular sources of polyamines for leukemic cell growth was shown by supplementation of the incubation medium with putrescine. Exogenous putrescine significantly enhanced the concentration of spermidine and spermine within the cell and increased the number of cells. The effect of OA on natural killer (NK) cell cytotoxicity was also examined. Rat peripheral blood mononuclear cells were used as effector cells and K 562 cells as targets. OA, progressively with dose, significantly decreased specific lysis when targets were preincubated with it. On the other hand, pretreatment of PBMC effector cells with OA, regardless of the applied concentration, did not affect the amount of 51Cr released from lysed cells. OA as a promoter of carcinogenesis stimulates proliferation of leukemic cells and impairs their responsiveness to NK activity. ODC/polyamine system and PK-C appear to be involved in OA action on K 562 cells. The presented observations are important from a practical point of view, since an elevated blood concentration of OA resulting from the impaired kidney function in hematological proliferative diseases may accelerate their progression.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009963 Orotic Acid An intermediate product in PYRIMIDINE synthesis which plays a role in chemical conversions between DIHYDROFOLATE and TETRAHYDROFOLATE. Potassium Orotate,Sodium Orotate,Zinc Orotate,Acid, Orotic,Orotate, Potassium,Orotate, Sodium,Orotate, Zinc
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000518 Eflornithine An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway. Difluoromethylornithine,alpha-Difluoromethylornithine,DL-alpha-Difluoromethylornithine,Eflornithine Hydrochloride,Eflornithine Monohydrochloride, Monohydrate,MDL-71,782 A,Ornidyl,RMI 71782,Vaniqa,alpha-Difluoromethyl Ornithine,DL alpha Difluoromethylornithine,MDL 71,782 A,MDL71,782 A,Ornithine, alpha-Difluoromethyl,alpha Difluoromethyl Ornithine,alpha Difluoromethylornithine
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015317 Biogenic Polyamines Biogenic amines having more than one amine group. These are long-chain aliphatic compounds that contain multiple amino and/or imino groups. Because of the linear arrangement of positive charge on these molecules, polyamines bind electrostatically to ribosomes, DNA, and RNA. Polyamines, Biogenic
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias

Related Publications

K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
March 1985, International journal of cancer,
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
January 1987, Bollettino dell'Istituto sieroterapico milanese,
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
January 1985, Cancer immunology, immunotherapy : CII,
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
January 1982, Journal of immunology (Baltimore, Md. : 1950),
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
June 1981, Hiroshima journal of medical sciences,
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
June 1983, Cellular immunology,
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
May 1990, Biochemical and biophysical research communications,
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
January 1988, Natural immunity and cell growth regulation,
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
September 2001, Leukemia research,
K Grzelkowska, and T Motyl, and J Ostrowski, and L Trzeciak
June 1983, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology,
Copied contents to your clipboard!